Table 5. Distribution of SUA and psychiatric outcomes across genotypes of SLC2A9 rs6855911 in men and women.
| GG | AG | AA | P-trend | |
| MEN (N) | 107 | 544 | 706 | |
| SUA (mean, SD) µmol/L | 317.96(76.11) | 352.57(69.60) | 367.63(74.75) | <0.001 |
| Lifetime pyschiatric disorders (N, %) | ||||
| Any anxiety disorders | 8(7.55) | 62(11.44) | 104(14.81) | 0.014 |
| GAD | 1(0.94) | 7(1.29) | 11(1.57) | 0.556 |
| Panic disorder | 0(0.00) | 9(1.66) | 14(1.99) | 0.203 |
| Agoraphobia | 2(1.89) | 7(1.29) | 18(2.57) | 0.211 |
| Social phobia | 6(5.66) | 42(7.75) | 77(10.98) | 0.019 |
| Current psychiatric disorders (N, %) | ||||
| Any anxiety disorders | 5(4.67) | 31(5.70) | 59(8.36) | 0.044 |
| Agoraphobia | 2(1.87) | 5(0.92) | 11(1.56) | 0.694 |
| Social phobia | 3(2.80) | 26(4.78) | 49(6.94) | 0.034 |
| WOMEN (N) | 108 | 653 | 780 | |
| SUA (mean, SD) µmol/L | 220.73(50.36) | 251.60(61.36) | 278.87(62.69) | <0.001 |
| Lifetime pyschiatric disorders (N, %) | ||||
| Any anxiety disorders | 23(21.50) | 161(24.73) | 170(21.88) | 0.463 |
| GAD | 3(2.80) | 20(3.07) | 21(2.70) | 0.767 |
| Panic disorder | 5(4.67) | 37(5.68) | 30(3.87) | 0.215 |
| Agoraphobia | 6(5.61) | 37(5.68) | 44(5.66) | 0.996 |
| Social phobia | 18(16.82) | 99(15.21) | 112(14.41) | 0.492 |
| Current psychiatric disorders (N, %) | ||||
| Any anxiety disorders | 19(17.59) | 89(13.63) | 92(11.79) | 0.083 |
| Agoraphobia | 5(4.63) | 23(3.52) | 24(3.08) | 0.404 |
| Social phobia | 16(14.81) | 69(10.57) | 73(9.36) | 0.108 |
GAD = generalized anxiety disorder; and SUA = serum uric acid.
The results are expressed as numbers and percentages except for SUA which is expressed as mean and standard deviation.
Sex-by-genotype interaction were significant for its effect on lifetime and current any anxiety disorders and social phobia (Table 4).